Xarelto Settlement Amounts
Xarelto (rivaroxaban) is a prescription blood-thinner that has been linked to serious internal bleeding injuries immediately or shortly after use of the medication. Lawsuits are now underway to compensate victims and their families for the manufacturer’s alleged failure to warn of significant bleeding risks.
At this time, the Xarelto litigation is in the early stages of the proceeding and no settlement agreements have been announced. Accordingly, attorneys may not provide specific dollar amounts or guarantee the monetary value of your case.
All potential claimants should, however, consult an attorney about the strengths and weaknesses of their claim and understand their legal options. As with any lawsuit, certain time limits apply that can restrict your ability to recover damages. Since it is unknown when a settlement could be reached, it is important that you begin the process now and safeguard your right to recovery.
Consult a Xarelto Attorney
Our Xarelto lawyers are national leaders in defective drug litigation with over 25 years’ experience in this complex area of law. We can provide an informed evaluation of your potential case at no cost and with no obligation to pursue a claim. Contact our office at (866) 808-2424 or through our brief online form at any time.
Xarelto Lawsuit Information
In July 2011, the FDA first approved Xarelto to reduce the risk of blood clots, deep vein thrombosis (DVT), and pulmonary embolism (PE) following hip or knee replacement surgery.
In November 2011, the FDA approved Xarelto to reduce the risk of stroke in patients with abnormal heart rhythm, or non-valvular atrial fibrillation.
In November 2012, the FDA expanded the approved uses of Xarelto to include the general treatment of DVT and PE, and to reduce the risk of recurrent DVT and PE following initial treatment.
The first reported Xarelto lawsuit was filed in February 2014 in Pennsylvania state court. The plaintiff alleged that she was hospitalized for severe internal and gastrointestinal bleeding after use of the medication. Over 150 similar cases have now been filed in the rapidly growing litigation.
Alleged Failure to Warn Xarelto Users
Our attorneys are investigating whether the manufacturer failed to properly warn users that Xarelto could cause irreversible internal bleeding. Unlike other blood-thinners, Xarelto does not have a known antidote that can stabilize bleeding emergencies once they occur. Also unlike other blood-thinners, Xarelto does not require that patients undergo routine blood monitoring, potentially subjecting patients to additional risks. Lawsuits against Xarelto manufacturers further allege that direct-to-consumer advertisements and other marketing materials downplayed or omitted important safety concerns while promoting the drug as safe and effective.
Prior Blood-Thinner Settlement
In May 2014, the maker of the blood-thinner Pradaxa agreed to pay $650 million to settle approximately 4,000 lawsuits for alleged internal bleeding injuries. That case is entitled In re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation, Case No. 3:12-md-02385, in the U.S. District Court for the Southern District of Illinois. The settlement agreement was announced two years after plaintiffs first began filing claims in federal court.
Start Your Case Now
The first step in any Xarelto lawsuit is to receive an informed evaluation of your claim. Since a Xarelto class action lawsuit has not been formed for internal bleeding victims, you will need your own attorney to represent you in an individual lawsuit. Contact our office for free legal help at (866) 808-2424 or online at any time.